MYGN - Conference and earnings call announcements

SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences. The UBS Global Healthcare Conference with a fireside chat on Tuesday, Nov. 10, 2026, at 1:15 pm ET.The 2026 Stephens Investment Conference with a fireside chat on Wednesday, Nov. 18, 2026, at 3:00 pm ET.The 38th Annual Piper Sandler Healthcare Conference with a fireside chat on Wednesday, Dec. 2, 2026, at 12:30 pm ET. The presentations will be available through live audio webcast links in the investor information section of Myriad’s website a

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients a

SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The BofA Securities 2026 Health Care Conference – 1-to-1 investor meetings taking place Wednesday, May 13, 2026.Goldman Sachs 47th Annual Global Healthcare Conference – fireside chat at 8:40 a.m. ET on Wednesday, June 10, 2026. The Goldman Sachs presentation will be available through live audio webcast links in the investor information section of Myriad's website at investor.myriad.com. About Myriad GeneticsMyriad Genetics is a leading molecular dia

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET). The presentation will be available through a live webcast and archived at investor.myriad.com.  About Myriad Genetics  Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing diseas

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be available through live audio webcast links in the investor information section of Myriad's website at investor.myriad.com.  About Myriad GeneticsMyriad Genetics is a leading molecular diagnos

SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET. Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com. About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and we

SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of genetic and tumor genomic testing solutions, coupled with its investments in research and product development, are advancing precision oncology and patient care. An oral abstract (#3007) titled "Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel:

SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Live and archived webcasts of all presentations can be viewed at investor.myriad.com. About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to adv

News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad's website at investor.myriad.com. An archived edition of the presentation will be available later that day. About Myriad GeneticsMyriad Genetics is a leading

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad's website at investor.myriad.com. An archived edition of the presentation will be available later that day. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops a

SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central Hotel in New York City on October 9, 2024. The in-person event will commence at 9:00 am EDT and last approximately two hours. Paul J. Diaz, President and CEO, and other members of the Myriad executive leadership team will discuss the company's long-term growth strategy, operational initiatives, scientific and clinical advancements reflected in its product pipeline, and long-term financial goals. For those interested in attending the event in person, please register here. For those unable to att

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences. The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET. Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medic

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company's Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR). At booth 25014, Myriad will highlight the value of genetic testing and genomic insights in guiding personalized cancer treatment decisions, as well as share information about upcoming product

SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST. The presentation will be available through a live webcast in the investor relations section of Myriad's website at investor.myriad.com. An archived edition of the presentation will be available later that day.  About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops an

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, November 15 at 2:00 p.m. ET. A live and archived webcast of the presentation can be viewed in the investor relations section of Myriad's website at www.myriad.com. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or d

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT. On Sept. 19, Myriad will host an in-person Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco. Paul J. Diaz, president and CEO, and other members of the Myriad executive leadership team will discuss commercialization strategies, clinical advancement and new product pipeline, and long-term financial goals. The Morgan Stanley firesid

SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will participate in the 44th Annual Goldman Sachs Global Healthcare Conference with a fireside chat on Tuesday, June 13, 2023 at 2:00 p.m. PT. A replay of the fireside chat will be available on the investor relations section of Myriad's website at www.myriad.com. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or

SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Myriad has recently made several advancements supporting its oncology footprint including hiring oncology experts to its leadership team as well as the addition of the Folate Receptor Alpha (FRα) biomarker to its oncology portfolio. "Our portfolio addition further expands upon our industry-leading suite of solutions spanning biomarker, germline and somatic t

SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, NV. Myriad management will participate in a fireside chat on Tuesday, May 9 at 3:00 p.m. PT. A live and archived webcast of the presentation can be viewed in the investor relations section of Myriad's website at www.myriad.com. About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of

SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences. The BTIG MedTech, Digital Health, Life Sciences and Diagnostic Tools Conference on Feb. 14, 2023. The 44th Annual Raymond James & Associates Institutional Investors Conference with a presentation on March 6, 2023, at 11:35 a.m. ET. The 43rd Annual Cowen Health Care Conference with a presentation on March 7, 2023, at 10:30 a.m. ET. The presentations at Raymond James and Cowen will be available through live audio webcast links in the investor information section of My

SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available through a live webcast on the Myriad Genetics Investor Relations website. An archived edition of the presentation will be available later that day. Also during the JPM Conference, Nicole Lambert, chief operating officer, will be participating in a panel discussion about global pre

SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will be presenting at two upcoming healthcare conferences. On Feb. 17, 2022, R. Bryan Riggsbee, chief financial officer, will participate in a fireside chat at the virtual BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference at 12 p.m. ET. On Feb. 18, 2022, Paul J. Diaz, president and CEO, and Riggsbee will participate in a fireside chat at the 11th annual SVB Leerink Global Healthcare Conference at 11:20 a.m. ET. The presentations will be available through live audio webcast links in the investor information section of Myriad's

SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021. Diaz will be joined by Bryan Riggsbee, chief financial officer of Myriad Genetics. The presentation will be available via a live audio webcast accessible through the investor section of the Myriad Genetics website at www.myriad.com. About Myriad Genetics Myriad Genetics Inc. is a leading genetic testing and precision medicine company

SALT LAKE CITY, May 05, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will discuss the company's transformation plan and growth initiatives during a fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference at 2:45 p.m. EDT on May 12, 2021. The presentation will be available via a live audio webcast accessible at the following direct link (link) or through the investor information section of Myriad's website at www.myriad.com. About Myriad Genetics Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to improving and trans

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is intensifying its focus on serving patients and healthcare providers in Women’s Health, Oncology and Mental Health. Paul J. Diaz, president and CEO at Myriad Genetics, and R. Bryan Riggsbee, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 19 at 10:30 a.m. EST. On February 24, 2021, Mr. Riggsbee will participate in a fireside c

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021. Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available via a live audio webcast accessible at the following direct